Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer.
Alkylating Agents
/ pharmacology
Antibiotics, Antineoplastic
/ pharmacology
Ataxia Telangiectasia Mutated Proteins
/ metabolism
Cell Line, Tumor
Checkpoint Kinase 1
/ genetics
DNA Damage
/ drug effects
Databases, Genetic
Drug Resistance, Neoplasm
/ genetics
Female
Genomic Instability
/ drug effects
Homologous Recombination
/ drug effects
Humans
Microscopy, Electron, Transmission
Mitomycin
/ pharmacology
Poly (ADP-Ribose) Polymerase-1
/ antagonists & inhibitors
Rad51 Recombinase
/ genetics
Recombinational DNA Repair
/ drug effects
Signal Transduction
/ genetics
Triple Negative Breast Neoplasms
/ genetics
CHK1
CIN70 score
DNA-damage response (DDR)
chromosomal instability (CIN)
homologous recombination (HR)
triple-negative breast cancer (TNBC)
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
17 01 2020
17 01 2020
Historique:
received:
10
12
2019
revised:
03
01
2020
accepted:
14
01
2020
entrez:
23
1
2020
pubmed:
23
1
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Chromosomal instability not only has a negative effect on survival in triple-negative breast cancer, but also on the well treatable subgroup of luminal A tumors. This suggests a general mechanism independent of subtypes. Increased chromosomal instability (CIN) in triple-negative breast cancer (TNBC) is attributed to a defect in the DNA repair pathway homologous recombination. Homologous recombination (HR) prevents genomic instability by repair and protection of replication. It is unclear whether genetic alterations actually lead to a repair defect or whether superior signaling pathways are of greater importance. Previous studies focused exclusively on the repair function of HR. Here, we show that the regulation of HR by the intra-S-phase damage response at the replication is of overriding importance. A damage response activated by Ataxia telangiectasia and Rad3 related-checkpoint kinase 1 (ATR-CHK1) can prevent replication stress and leads to resistance formation. CHK1 thus has a preferred role over HR in preventing replication stress in TNBC. The signaling cascade ATR-CHK1 can compensate for a double-strand break repair error and lead to resistance of HR-deficient tumors. Established methods for the identification of HR-deficient tumors for Poly(ADP-Ribose)-Polymerase 1 (PARP1) inhibitor therapies should be extended to include analysis of candidates for intra-S phase damage response.
Identifiants
pubmed: 31963582
pii: cells9010238
doi: 10.3390/cells9010238
pmc: PMC7017274
pii:
doi:
Substances chimiques
Alkylating Agents
0
Antibiotics, Antineoplastic
0
Mitomycin
50SG953SK6
PARP1 protein, human
EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1
EC 2.4.2.30
ATR protein, human
EC 2.7.11.1
Ataxia Telangiectasia Mutated Proteins
EC 2.7.11.1
CHEK1 protein, human
EC 2.7.11.1
Checkpoint Kinase 1
EC 2.7.11.1
RAD51 protein, human
EC 2.7.7.-
Rad51 Recombinase
EC 2.7.7.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Breast Cancer Res Treat. 2018 Aug;171(1):21-31
pubmed: 29736741
PLoS One. 2012;7(8):e44021
pubmed: 22937147
Clin Cancer Res. 2016 Aug 1;22(15):3764-73
pubmed: 26957554
Int J Biochem Cell Biol. 2012 Nov;44(11):1761-9
pubmed: 22743332
Br J Cancer. 2018 Jul;119(2):141-152
pubmed: 29867226
Nat Rev Mol Cell Biol. 2017 Oct;18(10):622-636
pubmed: 28811666
Breast Cancer Res Treat. 2010 Aug;123(1):189-96
pubmed: 20582464
Nat Genet. 2019 May;51(5):912-919
pubmed: 30988514
Breast Cancer Res Treat. 2016 Aug;159(1):41-53
pubmed: 27464795
Nat Commun. 2017 Oct 16;8(1):859
pubmed: 29038466
Nucleic Acids Res. 2004 Jul 13;32(12):3683-8
pubmed: 15252152
Crit Rev Biochem Mol Biol. 2017 Dec;52(6):696-714
pubmed: 28954549
Oncotarget. 2016 Mar 1;7(9):9732-41
pubmed: 26799421
Mol Cell. 2017 Jun 15;66(6):735-749
pubmed: 28622519
EMBO Rep. 2018 Sep;19(9):
pubmed: 30108055
Clin Cancer Res. 2018 Dec 15;24(24):6277-6287
pubmed: 30139880
Oncotarget. 2014 May 30;5(10):3261-72
pubmed: 24811120
Annu Rev Genet. 2011;45:247-71
pubmed: 21910633
Int J Cancer. 2013 May 1;132(9):2118-26
pubmed: 23065657
Cancer Res. 2011 May 15;71(10):3447-52
pubmed: 21270108
Cancer Res. 2019 Apr 1;79(7):1612-1623
pubmed: 30610086
Cell Cycle. 2008 Apr 1;7(7):859-64
pubmed: 18414031
Mol Cell. 2013 Nov 7;52(3):434-46
pubmed: 24207054
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
DNA Repair (Amst). 2005 Jun 8;4(6):687-98
pubmed: 15878310
Clin Cancer Res. 2017 Jun 15;23(12):3097-3108
pubmed: 27993965
Nat Cell Biol. 2006 Jan;8(1):37-45
pubmed: 16327781
Breast Cancer Res Treat. 2011 Jan;125(2):421-30
pubmed: 20352489
Mutat Res Rev Mutat Res. 2015 Jan-Mar;763:168-80
pubmed: 25795119
Clin Cancer Res. 2017 Dec 15;23(24):7521-7530
pubmed: 29246904
Breast. 2014 Jun;23(3):250-8
pubmed: 24636978
J Mol Biol. 2012 Aug 3;421(1):38-53
pubmed: 22579622
Cancer Res. 2001 Jun 15;61(12):4842-50
pubmed: 11406561
Cell Rep. 2017 Oct 10;21(2):333-340
pubmed: 29020621
Mol Cell Biol. 2000 Jun;20(11):3977-87
pubmed: 10805740
J Natl Cancer Inst. 2014 Jun 19;106(7):
pubmed: 24948741
Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16090-5
pubmed: 20805465
Annu Rev Genet. 2010;44:113-39
pubmed: 20690856
Mol Cell Biol. 2006 Apr;26(8):3319-26
pubmed: 16581803
Cancer Cell. 2012 Jul 10;22(1):106-16
pubmed: 22789542
Radiother Oncol. 2012 Mar;102(3):466-71
pubmed: 22326574
Lung Cancer. 2013 Dec;82(3):477-84
pubmed: 24113549
Cell Cycle. 2015;14(19):3190-202
pubmed: 26317153
Nucleic Acids Res. 2001 Nov 1;29(21):4352-60
pubmed: 11691922
Cancer Res. 2013 Jun 15;73(12):3683-91
pubmed: 23548269
Cancer Discov. 2015 May;5(5):488-505
pubmed: 25770156
Nat Genet. 2006 Sep;38(9):1043-8
pubmed: 16921376
Mol Cell. 2010 Oct 22;40(2):179-204
pubmed: 20965415
Nat Commun. 2013;4:2993
pubmed: 24356582
Nat Cell Biol. 2005 Feb;7(2):195-201
pubmed: 15665856
Genes Dev. 2013 Nov 15;27(22):2459-72
pubmed: 24240236
Mol Cell. 2012 Jul 27;47(2):320-9
pubmed: 22841003
Cancer Cell. 2003 Mar;3(3):247-58
pubmed: 12676583
Nat Rev Cancer. 2011 Jun 24;11(7):467-80
pubmed: 21701511
J Bone Miner Res. 2001 Aug;16(8):1486-95
pubmed: 11499871
Mol Cell Biol. 2000 Nov;20(21):8283-9
pubmed: 11027296
Mol Cell Biol. 2005 Aug;25(16):7158-69
pubmed: 16055725
Clin Cancer Res. 2014 Sep 15;20(18):4816-26
pubmed: 24963051